MAP2K7 and melanoma: Since 2013, Dabrafenib and Trametinb have proven to be a revolution for melanoma treatment; these drugs inhibits BRAF and MEK pathways and their use has become an important strategy to treat those forms of melanoma that present a mutation of BRAF (V600E).